Tickers

1. Composite Trajectory Verdict

For a commercial-stage biopharmaceutical company with multiple approved products, the income statement and cash flow statement carry the most weight because they directly reflect the trajectory of product revenue growth, operating leverage, and self-funding capacity; the balance sheet is important but secondary as it largely reflects the deployment of accumulated cash.

Composite Trajectory: Improving

Revenue, operating income, net income, and operating cash flow have grown consistently across the three most recent annual periods (2023–2025). Year-to-date 2026 results show accelerated top-line growth (+40.7% YoY) and substantial operating income expansion (+104% YoY), with operating cash flow also rising (+69% YoY). The balance sheet remains strong on an annual basis, with equity and working capital increasing 2024→2025, though the June 2026 quarterly snapshot shows a material liquidity reduction due to the Soleno acquisition. No single statement shows a deteriorating trend on a comparable-period basis.

2. Red Flags

• Cash and marketable securities declined 81% sequentially from $2,543.4M at Dec 31 2025 to $481.7M at Jun 30 2026, driven by $2.36B net cash paid for the Soleno acquisition (10-Q 2026-06-30, Condensed Balance Sheets; 10-Q 2026-06-30, Cash Flows from Investing Activities).
• Working capital fell 57% sequentially from $1,779.3M to $763.0M over the same period (10-Q 2026-06-30, MD&A – Information Regarding Our Financial Condition).
• Annual operating margin compressed from 24.2% in 2024 to 21.6% in 2025 despite 21% revenue growth, as R&D expense rose to 35.5% of revenue from 31.0% (10-K 2025-12-31, Consolidated Statements of Operations; 10-K 2025-12-31, MD&A – Operating Expenses).
• Effective tax rate increased annually from 24.8% (2023) to 29.8% (2024) to 32.2% (2025) (10-K 2025-12-31, MD&A – Provision for Income Taxes).
• Potential future milestone payments under existing collaborations total up to $15.35B (10-Q 2026-06-30, MD&A – Material Cash Requirements).
• DOJ civil investigative demand regarding INGREZZA sales and marketing practices (10-Q 2026-06-30, Legal Matters – U.S. Department of Justice Investigation).
• Paragraph IV patent challenge filed by Zydus for INGREZZA SPRINKLE (10-Q 2026-06-30, Legal Matters – Legal Proceedings).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Annual revenue grew from $1,887.1M (2023) to $2,355.3M (2024) to $2,860.5M (2025). Operating income rose from $250.9M to $570.5M to $619.1M, and net income from $249.7M to $341.3M to $478.6M over the same periods. Diluted EPS increased from $2.47 to $3.29 to $4.67. Year-to-date 2026 revenue reached $1,773.5M vs. $1,260.1M in YTD 2025 (+40.7%), with operating income of $344.9M vs. $169.2M (+104%) and net income of $342.3M vs. $115.4M (+197%). Quarterly Q2 2026 revenue was $959.0M vs. $687.5M in Q2 2025 (+39.5%), with net income of $144.4M vs. $107.5M (+34.3%).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Annual operating cash flow increased steadily: $389.9M (2023) → $595.4M (2024) → $782.7M (2025). Free cash flow (operating cash flow less capital expenditures) similarly rose: ~$362M → ~$557M → ~$749M. Year-to-date 2026 operating cash flow was $282.2M vs. $166.8M in YTD 2025 (+69%). Investing cash flow in YTD 2026 was -$641.6M, largely reflecting the $2.36B Soleno acquisition partially offset by $2.53B in debt security maturities/sales (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing cash flow in YTD 2026 was -$22.7M vs. -$121.2M in YTD 2025, with reduced share repurchases ($66.0M vs. $167.7M) and no convertible note settlements.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

On an annual basis (Dec 31 2024 → Dec 31 2025), total assets grew from $3,718.7M to $4,631.5M, cash and marketable securities from $1,815.6M to $2,543.4M, working capital from $1,217.0M to $1,779.3M, and total stockholders’ equity from $2,589.7M to $3,253.1M. Total liabilities increased modestly from $1,129.0M to $1,378.4M. The company held no debt after retiring the 2024 convertible notes. The June 30 2026 quarterly balance sheet reflects the Soleno acquisition: cash and marketable securities fell to $481.7M, goodwill of $500.6M and intangible assets of $2.2B were added, and working capital decreased to $763.0M, but equity still rose to $3,693.6M and a $1.0B revolving credit facility was available (10-Q 2026-06-30, Condensed Balance Sheets; 10-Q 2026-06-30, MD&A – Liquidity).

6. Data Gaps

• Quarterly balance sheet as of June 30 2025 (for YoY quarterly comparison)
• Standalone Q2 2026 cash flow statement (only YTD provided)
• Q3 and Q4 2026 quarterly results
• Full-year 2026 annual results
• Detailed breakdown of "Other" net product sales in quarterly periods
• Segment-level profitability (company reports single segment)
• Post-acquisition integration costs for Soleno beyond first six months